Compare ACV & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACV | PBYI |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.3M | 263.4M |
| IPO Year | N/A | N/A |
| Metric | ACV | PBYI |
|---|---|---|
| Price | $27.35 | $6.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 38.8K | ★ 368.1K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 9.20% | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.56 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.82 | $2.58 |
| 52 Week High | $23.74 | $6.48 |
| Indicator | ACV | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 64.96 |
| Support Level | $27.09 | $6.05 |
| Resistance Level | $27.79 | $6.29 |
| Average True Range (ATR) | 0.45 | 0.23 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 40.29 | 86.12 |
Virtus AllianzGI Diversified Income & Convertible Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation while seeking to provide downside protection against capital loss. It invests in a diversified portfolio of convertible securities, income-producing equity securities, and income-producing debt and other instruments of varying maturities, of which a majority of the managed assets are invested in convertibles.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.